Immune-Related Adverse Events and Efficacy of Checkpoint Inhibitors in Gastrointestinal Cancer

In a recent study, patients with gastrointestinal cancers who had immune-related adverse events while taking checkpoint inhibitors had progression-free survival of 32 months vs. 4 months in those who did not have side effects.